Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Nucleus Network, a global leader in early phase clinical research, today announced the acquisition of Hammersmith Medicines Research (HMR), one of the United Kingdom’s most respected early phase ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

As clinical trials become more complex, success depends on early collaboration, thoughtful protocol design, and practical ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Nucleus Network acquires UK-based clinical trial organisation, Hammersmith Medicines Research: Brisbane, Australia Tuesday, August 5, 2025, 14:00 Hrs [IST] Nucleus Network, a glob ...

Researchers at the University of New Mexico are preparing to launch a phase 1 clinical trial for an Alzheimer's vaccine after ...

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

Cardiol Therapeutics reports topline results from phase II ARCHER trial of CardiolRx in acute myocarditis patients: Toronto, Ontario Friday, August 8, 2025, 12:00 Hrs [IST] Cardio ...

City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...